Cleared Traditional

K013180 - RAPIDONE-ECSTASY TEST

K013180 is the FDA 510(k) clearance for RAPIDONE-ECSTASY TEST by American Bio Medica Corp.. It is a Class 2 Toxicology device (product code DJC) cleared through the Traditional 510(k) pathway after a 63-day FDA review.

K013180 · American Bio Medica Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2001
Decision
63d
Days
Class 2
Risk

K013180 is an FDA 510(k) clearance for the RAPIDONE-ECSTASY TEST. Classified as Thin Layer Chromatography, Methamphetamine (product code DJC), Class II - Special Controls.

Submitted by American Bio Medica Corp. (Columbia, US). The FDA issued a Cleared decision on November 26, 2001 after a review of 63 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3610 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all American Bio Medica Corp. devices

Submission Details

510(k) Number K013180 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 24, 2001
Decision Date November 26, 2001
Days to Decision 63 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
24d faster than avg
Panel avg: 87d · This submission: 63d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DJC Thin Layer Chromatography, Methamphetamine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3610
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJC Thin Layer Chromatography, Methamphetamine

All 11
Devices cleared under the same product code (DJC) and FDA review panel - the closest regulatory comparables to K013180.
BIO-VENTURE Rapid Amphetamine Test Cassette for OTC Use, BIO-VENTURE Rapid Oxazepam Test Cassette for OTC Use, BIO-VENTURE Rapid Cocaine Test Cassette for OTC Use, BIO-VENTURE Rapid Methamphetamine Test Cassette for OTC Use, BIO-VENTURE Rapid Morphine Test Cassette for OTC Use, BIO-VENTURE Rapid Marijuana Test Cassette for OTC Use, BIO-VENTURE Rapid Amphetamine Test Cassette for Rx Use, BIO-VENTURE Rapid Oxazepam Test Cassette for Rx Use, BIO-VENTURE Rapid Cocaine Test Cassette for Rx
K180878 · Shanghai Venture Bio-Tech Co., Ltd. · Dec 2018
OralTox Oral fluid Drug Test
K181305 · Premier Biotech, Inc. · Sep 2018
OralTox Oral Fluid Drug Test
K171403 · Premier Biotech, Inc. · Feb 2018
ONTRAK TESTCUP PRO-5, MODEL 1986678
K001356 · Roche Diagnostics Corp. · Jul 2000
DIALYSIS SYS., PDS 400 & RO 400
K781156 · Physio-Control Corp. · Oct 1978
KIDNEY, ARTIFICIAL
K781153 · Bd Becton Dickinson Vacutainer Systems Preanalytic · Oct 1978